This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared.In fact, demand for these drugs has been so strong that it even surpassed supply until the drugmakers took action to scale up manufacturing capacity -- and this may not let up. The obesity drug market may reach beyond $100 billion by 2030, according to Morgan Stanley Research.All of this has prompted investors to look for the next Lilly or Novo Nordisk -- a company that may join those giants in this high-growth market. Viking Therapeutics (NASDAQ: VKTX) seems to fit the bill, as it announced fantastic data from trials of its weight loss candidate last February -- and the stock delivered a 116% gain for the full year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool